These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32490276)

  • 21. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
    Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HCV Health Policy Developments in Response to the National Viral Hepatitis Action Plan: A Brief Update.
    Guo Y; Sims OT
    Soc Work Public Health; 2017 Feb; 32(2):77-81. PubMed ID: 27459698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
    Papatheodoridis GV; Hatzakis A; Cholongitas E; Baptista-Leite R; Baskozos I; Chhatwal J; Colombo M; Cortez-Pinto H; Craxi A; Goldberg D; Gore C; Kautz A; Lazarus JV; Mendão L; Peck-Radosavljevic M; Razavi H; Schatz E; Tözün N; van Damme P; Wedemeyer H; Yazdanpanah Y; Zuure F; Manns MP
    J Viral Hepat; 2018 Mar; 25 Suppl 1():6-17. PubMed ID: 29508946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conceptualising hepatitis C stigma: A thematic synthesis of qualitative research.
    Harris M; Guy D; Picchio CA; White TM; Rhodes T; Lazarus JV
    Int J Drug Policy; 2021 Oct; 96():103320. PubMed ID: 34261587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Securing sustainable funding for viral hepatitis elimination plans.
    Hatzakis A; Lazarus JV; Cholongitas E; Baptista-Leite R; Boucher C; Busoi CS; Deuffic-Burban S; Chhatwal J; Esmat G; Hutchinson S; Malliori MM; Maticic M; Mozalevskis A; Negro F; Papandreou GA; Papatheodoridis GV; Peck-Radosavljevic M; Razavi H; Reic T; Schatz E; Tozun N; Younossi Z; Manns MP
    Liver Int; 2020 Feb; 40(2):260-270. PubMed ID: 31808281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HCV Eradication: A Duty of the State, an Option for the Individual.
    Craxì L
    Adv Exp Med Biol; 2020; 1282():85-91. PubMed ID: 31808124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
    Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
    Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Framework for community-based models for treating hepatitis C virus.
    Pourmarzi D; Hall L; Smirnov A; Hepworth J; Rahman T; FitzGerald G
    Aust Health Rev; 2020 Jun; 44(3):459-469. PubMed ID: 31671288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrating public health policies in the epidemiological modeling of hepatitis C with LEHC tool: application in Austria.
    Lopes H; Baptista-Leite R; Franco D; Pirker R; Gschwantler M
    Wien Klin Wochenschr; 2021 May; 133(9-10):461-469. PubMed ID: 33331968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
    Goodyear T; Ti L; Carrieri P; Small W; Knight R
    Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017.
    Lazarus JV; Stumo SR; Harris M; Hendrickx G; Hetherington KL; Maticic M; Jauffret-Roustide M; Tallada J; Simojoki K; Reic T; Safreed-Harmon K;
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25052. PubMed ID: 29633562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study.
    Hassanin A; Kamel S; Waked I; Fort M
    Glob Health Sci Pract; 2021 Mar; 9(1):187-200. PubMed ID: 33795369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C: Is eradication possible?
    Lombardi A; Mondelli MU;
    Liver Int; 2019 Mar; 39(3):416-426. PubMed ID: 30472772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic.
    Bajis S; Applegate TL; Grebely J; Matthews GV; Dore GJ
    J Infect Dis; 2020 Nov; 222(Suppl 9):S758-S772. PubMed ID: 33245354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment as prevention and cure towards global eradication of hepatitis C virus.
    Hagan LM; Wolpe PR; Schinazi RF
    Trends Microbiol; 2013 Dec; 21(12):625-33. PubMed ID: 24238778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
    PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated early childhood development policy in Iran: a stakeholder analysis.
    Atashbahar O; Sari AA; Takian A; Olyaeemanesh A; Mohamadi E; Barakati SH
    BMC Health Serv Res; 2021 Sep; 21(1):971. PubMed ID: 34526031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C).
    Rance J; Lafferty L; Treloar C;
    Harm Reduct J; 2021 Apr; 18(1):46. PubMed ID: 33902595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive analysis of the HIV/AIDS policy-making process in Iran.
    Khodayari-Zarnaq R; Mosaddeghrad AM; Nadrian H; Kabiri N; Ravaghi H
    Health Res Policy Syst; 2019 Jul; 17(1):69. PubMed ID: 31324185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data.
    Palayew A; Stumo SR; Cooke GS; Hutchinson SJ; Jauffret-Roustide M; Maticic M; Harris M; Metwally AM; Razavi H; Lazarus JV;
    PLoS One; 2020; 15(7):e0235715. PubMed ID: 32722701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.